scholarly journals Sepantronium Bromide

2020 ◽  
Author(s):  
Keyword(s):  
Sepantronium Bromide

Sepantronium Bromide (YM155) Enhances Response of Human B-Cell Non-Hodgkin Lymphoma to Rituximab

2012 ◽  
Vol 343 (1) ◽  
pp. 178-183 ◽  
Author(s):  
Aya Kita ◽  
Keisuke Mitsuoka ◽  
Naoki Kaneko ◽  
Mari Nakata ◽  
Kentaro Yamanaka ◽  
...  
Keyword(s):  
B Cell ◽  
Hodgkin Lymphoma ◽  
Non Hodgkin Lymphoma ◽  
Human B Cell ◽  
Sepantronium Bromide

scholarly journals Author Correction: Early Cellular Responses of Prostate Carcinoma Cells to Sepantronium Bromide (YM155) Involve Suppression of mTORC1 by AMPK

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
David Danielpour ◽  
Zhaofeng Gao ◽  
Patrick M. Zmina ◽  
Eswar Shankar ◽  
Benjamin C. Shultes ◽  
...  
Keyword(s):  
Prostate Carcinoma ◽  
Cellular Responses ◽  
Carcinoma Cells ◽  
Sepantronium Bromide

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

scholarly journals Therapeutic potential of sepantronium bromide YM155 in gemcitabine-resistant human urothelial carcinoma cells

2013 ◽  
Vol 31 (2) ◽  
pp. 771-780 ◽  
Author(s):  
YEN TA HUANG ◽  
CHUAN CHU CHENG ◽  
TZU CHUN LIN ◽  
TED H. CHIU ◽  
PEI CHUN LAI
Keyword(s):  
Urothelial Carcinoma ◽  
Therapeutic Potential ◽  
Carcinoma Cells ◽  
Sepantronium Bromide

scholarly journals Adaptation to chronic exposure to sepantronium bromide (YM155), a prototypical survivin suppressant is due to persistent DNA damage-response in breast cancer cells

Oncotarget ◽  
2018 ◽  
Vol 9 (71) ◽  
pp. 33589-33600 ◽  
Author(s):  
Tasaduq H. Wani ◽  
Sreeraj Surendran ◽  
Vishnu S. Mishra ◽  
Jaya Chaturvedi ◽  
Goutam Chowdhury ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Dna Damage ◽  
Cancer Cells ◽  
Dna Damage Response ◽  
Chronic Exposure ◽  
Breast Cancer Cells ◽  
Damage Response ◽  
Sepantronium Bromide

scholarly journals Emerging Effects of Sepantronium Bromide (YM155) on MOLT-4 Cell Line Apoptosis Induction and Expression of Critical Genes Involved in Apoptotic Pathways

2019 ◽  
Vol 10 (1) ◽  
pp. 81-87
Author(s):  
Kobra Shojaei Moghadam ◽  
Majid Farshdousti Hagh ◽  
Mohammad Reza Alivand ◽  
Masoumeh Fardi ◽  
Ali Akbar Movassaghpour ◽  
...  
Keyword(s):  
Cell Line ◽  
Epithelial To Mesenchymal Transition ◽  
Target Genes ◽  
Lymphoblastic Leukemia ◽  
Annexin V ◽  
Apoptosis Induction ◽  
Mesenchymal Transition ◽  
Expression Levels ◽  
Apoptotic Pathways ◽  
Sepantronium Bromide

Purpose: Sepantronium bromide (YM155) is a Survivin inhibitor which recently advanced as an anticancer agent in phase II clinical trials. Survivin belongs to IAP (inhibitor of apoptosis) gene family and is a pivotal target for treatment due to its overexpression and oncogenic function in many malignancies, including acute lymphoblastic leukemia (ALL). Although survivin is a specific target for YM155, recent reports have shown that it has many other crucial targets that regulate its anti-apoptotic effects. The aim of this study was to investigate whether YM155 could have an effect on cell death-inducing genes as well as inducing apoptosis in T-ALL MOLT4- cell line. Methods: We treated MOLT-4 cells with increasing concentrations of YM155 and then cell viability was determined using MTT (methyl thiazolyl tetrazolium) assay. Also, the rate of induction of apoptosis in MOLT-4 cells and the target genes expression levels were evaluated by Annexin V/PI and real-time PCR, respectively. Results: YM155 inhibited cell growth in MOLT-4 cells. This outcome is achieved by inducing apoptosis and a significant increase in the expression level of P53, MiR-9, caspase 3 and decreasing the mRNA expression levels of survivin, Sirtuin1(SIRT1), member of anti-apoptotic proteins family (Bcl-2), and epithelial-to-mesenchymal transition (EMT) initiating factors Snail1and Zeb2. Conclusion: The results showed that use of YM155 can be a potential drug therapy in T-ALL patients with promising effects on apoptosis induction.

Sign in / Sign up

Export Citation Format

Share Document